Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
FENCthis companyFennec Pharmaceuticals Inc.	$10.64	-21.39×	6.28×	4.93×	-24.6×	-158.5%	91.6%	-14.2%	-21.8%	-27.8%	-10.7%	-5.7%	0×	4.93×	-3.05×	6.34×	0.0%	5	4.08	1	D+
AARDAardvark Therapeutics, Inc. Common Stock	$1.35	-4.97×	2.69×	0×	-4.17×	71.6%	0.0%	0.0%	0.0%	-54.0%	-58.6%	-18.9%	0×	0.81×	0×	10.61×	0.0%	1	-1.98	3	B-
AVTXAvalo Therapeutics, Inc.	$7.02	-3.11×	2.93×	4,125.96×	-2.96×	-86.5%	100.0%	-123601.7%	-132642.4%	-94.2%	-70.2%	-21.1%	0.03×	0.17×	0×	8.14×	0.0%	2	4.43	2	B-
BDTXBlack Diamond Therapeutics, Inc.	$1.84	6.23×	1.23×	1.97×	5.99×	520.8%	99.5%	28.4%	32.0%	19.9%	15.2%	21.4%	0.17×	-0.1×	0×	8.42×	0.0%	1	-3.44	3	B-
CRBUCaribou Biosciences, Inc.	$0.46	-1×	1.22×	13.31×	-1.13×	-908.6%	67.3%	-1220.5%	-1327.4%	-121.2%	-89.8%	-75.7%	0.22×	-0.1×	0×	5.71×	0.0%	3	-7.25	2	C
ENTAEnanta Pharmaceuticals, Inc.	$11.49	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
Peer median	—	-3.11×	2.69×	3.91×	-2.96×	-86.5%	93.0%	-130.7%	-125.4%	-94.2%	-58.6%	-18.9%	0.17×	-0.1×	0×	8.14×	0.0%	2	-1.98	2	—